Evidence map›Paper›PMID 36581993›Full record

ArticleBreast cancer research : BCR2022

Towards resolution of the intron retention paradox in breast cancer.

Jaynish S Shah, Michael J G Milevskiy, Veronika Petrova, Amy Y M Au, Justin J L Wong, Jane E Visvader, Ulf Schmitz, John E J Rasko

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jaynish S ShahComputational BioMedicine Laboratory Centenary Institute, The University of Sydney, Camperdown, Australia.
Michael J G MilevskiyACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Veronika PetrovaComputational BioMedicine Laboratory Centenary Institute, The University of Sydney, Camperdown, Australia.
Amy Y M AuGene and Stem Cell Therapy Program Centenary Institute, The University of Sydney, Locked Bag No. 6, Newtown, NSW, 2042, Australia.
Justin J L WongEpigenetics and RNA Biology Program Centenary Institute, The University of Sydney, Camperdown, 2050, Australia.
Jane E VisvaderACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Ulf Schmitz *Computational BioMedicine Laboratory Centenary Institute, The University of Sydney, Camperdown, Australia. ulf.schmitz@jcu.edu.au.
John E J Rasko *Gene and Stem Cell Therapy Program Centenary Institute, The University of Sydney, Locked Bag No. 6, Newtown, NSW, 2042, Australia. j.rasko@centenary.org.au.
Centenary Institute · AUUniversity of Sydney · AUUniversity of Melbourne · AUWalter and Eliza Hall Institute of Medical Research · AU

Funding

Cancer Council NSW RG11-12Cancer Council NSW RG20-12National Health and Medical Research Council, Australia 1177305National Health and Medical Research Council, Australia 1196405
6 · The paper itself

Abstract

backgroundAfter many years of neglect in the field of alternative splicing, the importance of intron retention (IR) in cancer has come into focus following landmark discoveries of aberrant IR patterns in cancer. Many solid and liquid tumours are associated with drastic increases in IR, and such patterns have been pursued as both biomarkers and therapeutic targets. Paradoxically, breast cancer (BrCa) is the only tumour type in which IR is reduced compared to adjacent normal breast tissue.

methodsIn this study, we have conducted a pan-cancer analysis of IR with emphasis on BrCa and its subtypes. We explored mechanisms that could cause aberrant and pathological IR and clarified why normal breast tissue has unusually high IR.

resultsStrikingly, we found that aberrantly decreasing IR in BrCa can be largely attributed to normal breast tissue having the highest occurrence of IR events compared to other healthy tissues. Our analyses suggest that low numbers of IR events in breast tumours are associated with poor prognosis, particularly in the luminal B subtype. Interestingly, we found that IR frequencies negatively correlate with cell proliferation in BrCa cells, i.e. rapidly dividing tumour cells have the lowest number of IR events. Aberrant RNA-binding protein expression and changes in tissue composition are among the causes of aberrantly decreasing IR in BrCa.

conclusionsOur results suggest that IR should be considered for therapeutic manipulation in BrCa patients with aberrantly low IR levels and that further work is needed to understand the cause and impact of high IR in other tumour types.

Indexed as

Breast NeoplasmsBreastCell ProliferationFemaleHumansIntronsAdipocytesAlternative splicingCancer transcriptomicsLuminal B breast cancerPatient stratification

Identifiers

PMID36581993
PMCPMC9798573
OpenAlexW4313331708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.